Summary:
- The article discusses the FDA's approval of Fujirebio's Lumipulse G β-Amyloid Ratio (1-42/1-40) test, which is a new diagnostic tool for Alzheimer's disease.
- The test measures the levels of two different forms of the amyloid-beta protein in the blood, which can help identify individuals with Alzheimer's disease or at risk of developing it.
- This approval is significant as it provides a non-invasive and more accessible way to diagnose Alzheimer's, which is crucial for early intervention and treatment.